Navigation Links
Vanda Pharmaceuticals to Announce Fourth Quarter 2010 Financial Results on February 10, 2011
Date:2/1/2011

ROCKVILLE, Md., Feb. 1, 2011 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders, today announced it will release results for the fourth quarter of 2010, on Thursday, February 10, 2011, before the market opens. A full text copy of the release will be disseminated at that time.

Mihael H. Polymeropoulos, M.D., President and Chief Executive Officer, will host a conference call to discuss the results at 10:00 AM ET on Thursday, February 10, 2011.  Also participating on the call will be James Kelly, Senior Vice President and Chief Financial Officer.  To participate in the conference call, dial the appropriate number below shortly before the 10:00 AM start time and ask for the Vanda Pharmaceuticals conference call hosted by Dr. Polymeropoulos.The teleconference dial-in numbers are as follows:Domestic callers 1-800-591-6942International callers 1-617-614-4909Participant Passcode 43128562The conference call will be broadcast simultaneously and archived on the Company's website, www.vandapharma.com. Investors should go to the website at least 15 minutes early to register, download, and install any necessary audio software.

A replay of the call will be available on Thursday, February 10, 2011, beginning at 1:00 PM ET and will be accessible until Thursday, February 17, 2011, at 5:00 PM ET. The replay call-in number is 1-888-286-8010 for domestic callers and 1-617-801-6888 for international callers. The access number is 66575807.

ABOUT VANDA PHARMACEUTICALS INC.:Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of products for central nervous system disorders.  For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.


'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Vanda Pharmaceuticals to Announce Second Quarter 2010 Financial Results on August 5, 2010
2. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
3. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
4. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
5. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
6. Vanda Pharmaceuticals Reports First Quarter 2009 Results
7. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
8. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
9. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
10. Onyx Pharmaceuticals Receives Fast Track Designation for Carfilzomib; Company Initiates Rolling NDA Submission for Accelerated Approval
11. Cadence Pharmaceuticals Announces U.S. Launch and Availability of OFIRMEV™ (acetaminophen) Injection
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... 2017 , ... DaVita Clinical Research (DCR), a ... device development, and Prism Clinical Research , a leader in providing fully ... Clinical Trials (VCT) has been selected by both companies as an exclusive ...
(Date:1/18/2017)... Portland, OR (PRWEB) , ... January 18, 2017 ... ... modules that provide essential device-to-computer interconnect using USB or PCI Express, announced the ... Altera Cyclone V E FPGA into a compact business-card sized form factor suitable ...
(Date:1/18/2017)... ... , ... Executive search firm Slone Partners proudly supports the ... advancement of the clinical trials segment. Hosted in Miami, this conference brings together ... management. , As executive talent specialists in the industries central to clinical ...
(Date:1/18/2017)... ... ... Researchers from a new study are stating that if levels of the blood ... this indicates there is still remaining prostate cancer cells that are more likely to come ... always been an indicator of whether a man’s prostate cancer is growing or not,” ...
Breaking Biology Technology:
(Date:1/11/2017)...  Michael Johnson, co-founder of Visikol Inc. a company originally funded ... named to the elite "Forbes 30 Under 30" list in the ... in 20 fields nationwide to be recognized as a leader in ... selected. ... currently a PhD candidate at Rutgers University. ...
(Date:1/4/2017)...  For the thousands of attendees at this year,s International Consumer Electronics ... and biometric measurement devices and services, will be featuring its new line ... A&D Medical,s special CES Exhibit Suite , the new upper arm ... company,s WellnessConnected product platform.  ... ...
(Date:12/22/2016)... 2016 SuperCom (NASDAQ:   ... the e-Government, Public Safety, HealthCare, and Finance sectors announced today that ... selected to implement and deploy a community-based supportive services program to ... , further expanding its presence in the state. ... This new program, which is ...
Breaking Biology News(10 mins):